Payment overview · 2025
General Payments
$276.73
17 reported records · 7 companies
Healthcare provider profile · identity verified
Adam J Bihl, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ONTARIO, OH · NPI 1164465480
Verified facts
What the public records show
CMS Open Payments records show Adam J Bihl, M.D. received $276.73 in general payments during 2025 across 17 reported records.
Lilly USA, LLC accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Otezla, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.42 | 21.5% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.72 | 20.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.98 | 18.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.21 | 17.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.10 | 10.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.88 | 6.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.42 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $276.73 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.42 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $55.72 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.98 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.98 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.21 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 108 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 142 |
| Lisinopril | Lisinopril | 400 | 111 |
| Omeprazole | Omeprazole | 353 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 81 |
| Montelukast Sodium | Montelukast Sodium | 252 | 75 |
| Celecoxib | Celecoxib | 215 | 91 |
| Gabapentin | Gabapentin | 190 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 50 |
| Losartan Potassium | Losartan Potassium | 182 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 58 |
| Simvastatin | Simvastatin | 166 | 49 |
| Prednisone | Prednisone | 162 | 108 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 66 |
| Metformin Hcl | Metformin Hcl | 147 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 41 |
| Meloxicam | Meloxicam | 130 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 34 |
| Mounjaro | Tirzepatide | 108 | 18 |
| Clonazepam | Clonazepam | 107 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 102 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 28 |
| Potassium Chloride | Potassium Chloride | 100 | 32 |
| Glimepiride | Glimepiride | 99 | 31 |
| Tramadol Hcl | Tramadol Hcl | 99 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 31 |
| Trazodone Hcl | Trazodone Hcl | 94 | 25 |
| Eliquis | Apixaban | 93 | 28 |
| Synthroid | Levothyroxine Sodium | 90 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 25 |
| Famotidine | Famotidine | 84 | 18 |
| Furosemide | Furosemide | 74 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 19 |
| Atenolol | Atenolol | 65 | 21 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 63 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 31 |
| Carvedilol | Carvedilol | 61 | 16 |
| Memantine Hcl | Memantine Hcl | 61 | 15 |
| Allopurinol | Allopurinol | 60 | 16 |
| Buspirone Hcl | Buspirone Hcl | 56 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 51 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 41 |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 26 |
| Trulicity | Dulaglutide | 43 | 12 |
| Azelastine Hcl | Azelastine Hcl | 42 | 25 |
| Ozempic | Semaglutide | 42 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 25 |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 11 |
| Spironolactone | Spironolactone | 38 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Cefdinir | Cefdinir | 34 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 11 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 15 |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 21 |
| Amoxicillin | Amoxicillin | 27 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 18 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276.73 · 17 records | Lilly USA, LLC | BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, GARDASIL 9, M-M-R II, MOUNJARO, OTEZLA, Ozempic, REPATHA, VAXELIS, VOQUEZNA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error